Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0112035" target="_blank" >RIV/00843989:_____/25:E0112035 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603DJM

Výsledek na webu

<a href="https://doi.org/10.1007/s43440-025-00776-9" target="_blank" >https://doi.org/10.1007/s43440-025-00776-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s43440-025-00776-9" target="_blank" >10.1007/s43440-025-00776-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study

Popis výsledku v původním jazyce

Background: Serum canrenone concentrations have so far only been measured in patients with acute heart failure or heart failure with preserved ejection fraction. The results of these studies showed that low or undetectable canrenone concentrations could contribute to the lack of pharmacological effect of spironolactone, while patients with detectable canrenone concentrations had significantly higher potassium concentrations. However, no detailed information on serum canrenone concentrations in patients with heart failure with reduced ejection fraction (HFrEF) has been published to date. The aim of the study was to determine serum canrenone concentrations in samples collected from patients with HFrEF during routine medical care and correlate them with selected clinical parameters such as left ventricular ejection fraction (LVEF), systolic and diastolic blood pressure, and the levels of N-terminal pro-B-type natriuretic peptide, serum potassium, liver enzymes, and renal function markers. Methods: This cross-sectional study analyzed data from 64 patients treated for HFrEF with oral spironolactone. Patients were recruited from the Cardiology Outpatient Clinic of the University Hospital, Ostrava, Czech Republic. Blood samples were collected in an outpatient setting from each patient between November 2022 and October 2023 as part of a routine examination to determine steady-state serum canrenone concentrations. Results: Serum canrenone concentrations ranged from 5.0 to 336.2 µg/L. A correlation was observed between canrenone concentration and both the daily spironolactone dose and dose per kilogram of body weight. However, wide inter-individual variability was observed in canrenone concentrations achieved after administering the same dose of spironolactone and in the concentration-to-dose ratio. Patients with LVEF < 30% used the same dose per day and kilogram of body weight as patients with LVEF ? 30% but achieved significantly higher canrenone concentrations. A correl...

Název v anglickém jazyce

Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study

Popis výsledku anglicky

Background: Serum canrenone concentrations have so far only been measured in patients with acute heart failure or heart failure with preserved ejection fraction. The results of these studies showed that low or undetectable canrenone concentrations could contribute to the lack of pharmacological effect of spironolactone, while patients with detectable canrenone concentrations had significantly higher potassium concentrations. However, no detailed information on serum canrenone concentrations in patients with heart failure with reduced ejection fraction (HFrEF) has been published to date. The aim of the study was to determine serum canrenone concentrations in samples collected from patients with HFrEF during routine medical care and correlate them with selected clinical parameters such as left ventricular ejection fraction (LVEF), systolic and diastolic blood pressure, and the levels of N-terminal pro-B-type natriuretic peptide, serum potassium, liver enzymes, and renal function markers. Methods: This cross-sectional study analyzed data from 64 patients treated for HFrEF with oral spironolactone. Patients were recruited from the Cardiology Outpatient Clinic of the University Hospital, Ostrava, Czech Republic. Blood samples were collected in an outpatient setting from each patient between November 2022 and October 2023 as part of a routine examination to determine steady-state serum canrenone concentrations. Results: Serum canrenone concentrations ranged from 5.0 to 336.2 µg/L. A correlation was observed between canrenone concentration and both the daily spironolactone dose and dose per kilogram of body weight. However, wide inter-individual variability was observed in canrenone concentrations achieved after administering the same dose of spironolactone and in the concentration-to-dose ratio. Patients with LVEF < 30% used the same dose per day and kilogram of body weight as patients with LVEF ? 30% but achieved significantly higher canrenone concentrations. A correl...

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacological reports

ISSN

1734-1140

e-ISSN

2299-5684

Svazek periodika

77

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

1751-1759

Kód UT WoS článku

001561098800001

EID výsledku v databázi Scopus

—